These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


180 related items for PubMed ID: 18815562

  • 1. Octreotide LAR in carcinoid: how to dose?
    Yao JC, Kvols LK.
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract] [Full Text] [Related]

  • 2. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF, Hager DF.
    Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract] [Full Text] [Related]

  • 3. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
    Woltering EA, Salvo VA, O'Dorisio TM, Lyons J, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G.
    Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
    [Abstract] [Full Text] [Related]

  • 4. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [Abstract] [Full Text] [Related]

  • 5. Role of Somatostatin Analogues in Oncology. European Neuroendocrine Tumor Network (ENET). February 24-27, 2000, Innsbruck, Austria. Proceedings.
    Digestion; 2000 Oct; 62 Suppl 1():1-108. PubMed ID: 11001649
    [No Abstract] [Full Text] [Related]

  • 6. Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location.
    Warman M, Halperin D, Poria Y, Huszar M, Idelevich E.
    Otolaryngol Head Neck Surg; 2009 Mar; 140(3):437-8. PubMed ID: 19248962
    [No Abstract] [Full Text] [Related]

  • 7. Octreotide.
    Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ.
    N Engl J Med; 1996 Jan 25; 334(4):246-54. PubMed ID: 8532003
    [No Abstract] [Full Text] [Related]

  • 8. The tumour vanishes.
    Todd JF, Meeran K.
    Clin Endocrinol (Oxf); 2000 Dec 25; 53(6):663-4. PubMed ID: 11155085
    [No Abstract] [Full Text] [Related]

  • 9. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.
    Woltering EA, Mamikunian PM, Zietz S, Krutzik SR, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G.
    Pancreas; 2005 Nov 25; 31(4):392-400. PubMed ID: 16258376
    [Abstract] [Full Text] [Related]

  • 10. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D.
    World J Gastroenterol; 2015 Feb 14; 21(6):1945-55. PubMed ID: 25684964
    [Abstract] [Full Text] [Related]

  • 11. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C, Shih YC, Xu Y, Yao JC.
    Cancer; 2014 Jul 01; 120(13):2039-49. PubMed ID: 24676892
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.
    Drug Des Devel Ther; 2015 Jul 01; 9():5075-86. PubMed ID: 26366058
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M, Sasano H.
    Anticancer Res; 2007 Jul 01; 27(4B):2231-9. PubMed ID: 17695508
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET, Oberg K.
    Cancer Chemother Biol Response Modif; 2003 Jul 01; 21():535-46. PubMed ID: 15338762
    [No Abstract] [Full Text] [Related]

  • 20. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
    Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B.
    Ann Oncol; 2004 Jun 01; 15(6):966-73. PubMed ID: 15151956
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.